Our current portfolio of intellectual properties (“IPs”) is adequate to spearhead our commercialisation plan focusing on personalised mRNA mapping and miRNA-based early diagnostics for cancer markers.
IPs for Platform 1 PERSONALISED mRNA MAPPING for HEALTH-RISK PROFILING
- Strategic immunological antigens or peptides for immune health
- Bioactive compositions for protection against infectious agents
- Bioactive compositions for directing cell movement and stimulating immune health
- Bioactive compositions for immunomodulation and anti-tumour activities
- Bioactive compositions for neuroprotection and brain health
- Bioactive compositions for sedative, anxiolytic, hypnotic, and anticonvulsant activities
IPs for Platform 2 miRNA-BASED BIOMARKERS DIAGNOSTICS
- Psoriasis
- Cutaneous Squamous Carcinoma
- Brain Cancer
- Head and Neck Cancer
- Liver Cancer
- Colorectal Cancer and Alzheimer’s Disease